minocycline and Genital-Diseases--Female

Topics: Chlamydia Infections; Female; Genital Diseases, Female; Homosexuality; Humans; Infertility, Male; Lymphogranuloma Venereum; Male; Minocycline; Sexually Transmitted Diseases; Tetracyclines; Urethritis; Uterine Cervicitis

The aim of this study was to investigate the relationships between treatment outcomes of patients with urogenital Chlamydia trachomatis infections and minimum inhibitory concentrations (MICs) and drug resistance genes.. The clinical data of 92 patients diagnosed with Chlamydia trachomatis (C. trachomatis) infections were collected. Of these patients, 28 received regular treatment with azithromycin and 64 received minocycline. All patients underwent three monthly follow-ups after the completion of treatment. The microdilution method was used for the in vitro susceptibility tests. The acquisition of 23S rRNA mutations and presence of the tet(M) gene were detected by gene amplification and sequencing.. The MICs of azithromycin, clarithromycin, erythromycin, tetracycline, doxycycline, and minocycline were comparable for isolates from the treatment failure and treatment success groups. Higher detection rates of 23S rRNA gene mutations and tet(M) were found in the treatment failure group (57.14% and 71.43%, respectively) than in the treatment success group (14.29% and 30.23%, respectively) (p < 0.05). The A2057G, C2452A, and T2611C gene mutations of 23S rRNA were detected in eight clinical isolates from the azithromycin treatment failure group, while the T2611C gene mutation was detected in one clinical strain from the treatment success group.. The detection of resistance genes could better explain the high treatment failure rate than the MIC results in patients with urogenital C. trachomatis infections, highlighting the need for genetic antimicrobial resistance testing in infected patients.

Topics: Adult; Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Drug Resistance, Bacterial; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; RNA, Ribosomal, 23S; Treatment Failure; Urinary Tract Infections; Young Adult

Following intravaginal inoculation of progesterone-treated outbred mice with Chlamydia trachomatis MoPn, 4 to 6 log10 inclusion-forming units were recovered in vaginal swabs for 21 days but all animals were culture negative after 28 days. Serum antibody titers were elevated and remained high for at least 70 days. Between 28 and 70 days, upper tract infection (inflammation and distension of the uterine horns, occlusion of oviducts with inflammatory exudate, pyosalpinx, and hydrosalpinx) was seen in > 80% of the animals. Mice were dosed orally, commencing at 7 days after infection, with minocycline, doxycycline, or amoxicillin-clavulanate. Further groups received azithromycin either as a single high dose or as lower once-daily doses. In addition, minocycline and amoxicillin-clavulanate were administered at 24 h after infection, and this early treatment prevented elevation of antibody titers whereas delayed therapy did not. Vaginal swabs from mice in all treatment regimens were culture negative except for 25% of mice receiving either early amoxicillin-clavulanate or low-dose azithromycin, which yielded low numbers (20 to 70 inclusion-forming units) of chlamydiae. Numbers of fertile mice in the early treatment regimens and their litter sizes were similar to those of noninfected controls, although 25% of amoxicillin-clavulanate-treated mice had unilateral hydrosalpinges. In comparison, 88% of untreated mice developed hydrosalpinges and only 25% conceived. Delayed dosing did not affect the outcome of amoxicillin-clavulanate therapy but did diminish the protective efficacy of minocycline such that 50% of treated mice had either unilateral hydrosalpinges or ovarian abscesses. Doxycycline and azithromycin were highly effective in restoring fertility. This model makes possible the study of both short- and long-term outcomes of chlamydial infection.

Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Animals; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Clavulanic Acids; Disease Models, Animal; Doxycycline; Drug Therapy, Combination; Female; Fertility; Genital Diseases, Female; Mice; Microbial Sensitivity Tests; Minocycline; Progesterone; Time Factors; Vagina

Among 226 outpatients, 30(13.3%) harboured Chlamydia trachomatis in the cervix. C. trachomatis was found in 15.1% of the patients with lower genital tract infection, 8.0% of pregnant women, 0.0% of sterile women, 14.3% of patients with pelvic inflammation and 88.9% of sexual partners respectively. The frequency of C.trachomatis infection in those 50 years old or more was 0.0%. One hundred and sixty-six women were also found to have titers of serum antibody to C.trachomatis. Serum IgG antibodies were found in 64 of 166(38.6%). Serum IgG antibodies were positive in 66.7% of the Chlamydia-positive women (20/30 subjects), whereas the positive rate was 31.0% in the Chlamydia-negative women (39/126 cases). In 40.0% of chlamydia positive patients, there was seen a significant rise in the number of paired sera. For C. trachomatis infection treatment with minocycline 100mg p.o. twice a day was effective (100%).

Topics: Chlamydia Infections; Chlamydia trachomatis; Female; Genital Diseases, Female; Humans; Immunoglobulin G; Minocycline; Pregnancy

Topics: Chlamydia Infections; Female; Genital Diseases, Female; Humans; Minocycline; Tetracyclines

Topics: Adolescent; Adult; Chlamydia Infections; Chlamydia trachomatis; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Male; Middle Aged; Minocycline; Tetracyclines

A new macrolide antibiotic, rosamicin, was shown to have much greater activity in vitro against ureaplasmas isolated from humans than erythromycin or the tetracyclines tested. A marked ureaplasmacidal effect was also shown.

Topics: Anti-Bacterial Agents; Doxycycline; Erythromycin; Female; Genital Diseases, Female; Humans; Leucomycins; Minocycline; Time Factors; Ureaplasma

Topics: Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Male; Minocycline; Sex Factors; Tetracycline; Vestibule, Labyrinth